Absenteeism among employees treated for depression

Journal of Occupational and Environmental Medicine

Volumn 41, Issue 7, 1999, Pages 605-611

  Claxton, Ami J ^a   Chawla, Anita J ^b   Kennedy, Sean ^c  

^a ELI LILLY AND COMPANY   (United States)

^b MEDSTAT GROUP   (United States)

^c MEDSTAT Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST; DEPRESSION; EMPLOYMENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; RETROSPECTIVE STUDY;

ABSENTEEISM; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DEPRESSION; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 0033043425     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199907000-00009     Document Type: Article

References (28)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-months prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:9-19.
2. Greenberg P, Stiglin LE, Finkelstein S, Berndt E. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
3. Murray CJ, Lopez AD. The Global Burden of Disease. Geneva, Switzerland: World Health Organization; 1996.
4. Greenberg P, Stiglin LE, Finkelstein S, Berndt E. Depression: a neglected major illness. J Clin Psychiatry. 1993;54:419-424.
5. Broadhead WE, Blazer DG, George L, Tze CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264: 2525-2528.
6. Conti D, Burton W. The economic impact of depression in a workplace. J Occup Med. 1994;36:983-988.
7. Greenberg R, Bornstein RF, Zborowski MJ, Fisher S, Greenberg M. A metaanalysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis. 1994;182:547-551.
8. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683-687.
9. Workman E, Short D. Atypical antidepressants versus imipramine in the treatment of major depression: a metaanalysis. J Clin Psychiatry. 1993;54:5-12.
10. Canadian Coordinating Office of Health Technology Assessment. A Clinical and Economic Evaluation of Selective Serotonin Reuptake Inhibitors in Major Depression. Ontario, Canada: Canadian Coordinating Office of Health Technology Assessment; 1998.
11. Gregor K, Overhage JM, Coon SJ, MacDonald RM. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther. 1994;16:306-315.
12. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Managed Care. 1996;2:1239-1246.
13. Deleted in proof.
14. Montejo AL, Gilaberte I, Fombellida C, Hylan TR, Sacristan JA. Patron de uso de los nuevos antidepresivos en la practica clinica. Actas Luso Esp Neurol Psiquiatr. 1998;26:75-82.
15. Sclar DA, Robison LM, Skaer T, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995; 23:395-412.
16. Hylan TR, Crown WH, Meneades L, Melfi C, Croghan TW, Buesching DP. SSRI and TCA antidepressant selection and health care costs: a multivariate analyses. J Affect Dis. 1998;47:71-79.
17. Sturm R, Wells K. How can care for depression become more cost-effective? JAMA. 1995;273:51-58.
18. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49:761-768.
19. Russell, JM, Finkelstein SN, Berndt ER, et al. Economic impact of improved work performance after treatment of chronic depression. Poster presented at: ECNP Congress, June 23-27, 1996, Melbourne, Australia.
20. Finkelstein S, Berndt ER, Greenberg P, et al. Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Psychopharmacol Bull. 1996;32:33-40.
21. Keith A, Berndt ER, Finkelstein S, et al. Improvement in subjective work performance after treatment of chronic depression. Poster presented at: International Health Economics Association Annual Meeting, May 19-23, 1996, Vancouver, British Columbia.
22. Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S. Clinical and economic comparisons of sertraline and fluoxetine in the treatment of depression: a six-month double-blind study in a primary-care setting in France. Pharmacoeconomics. 1998;13:157-169.
23. Tollefson GD, Souetre E, Thomander L, Potvin JH. Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes. Int Clin Psychopharmacol. 1993;8:281-293.
24. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362.
25. Lejoyeux M, Ades J, Mourad I, Solomon J, Disalver S. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs. 1996;5:278-292.
26. Montgomery SA. Prophylaxis in recurrent unipolar depression: a new indication for treatment studies. J Psychopharmacol. 1989;3:47-53.
27. Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching DP, Oster G. Predictors of a medical offset effect among patients receiving antidepressant therapy. Am J Psychiatry. 1998;155: 824-827.
28. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128-1132.